Product Code: GDHCER104-15
Sjogren's syndrome (SS) is a chronic systemic autoimmune disease characterized by chronic inflammation of the exocrine glands and is one of the three most common autoimmune diseases in the US. Due to the lack of validated and universally accepted diagnostic criteria for diagnosing SS, a large variation can be seen in the rates of this disease. The three most commonly utilized diagnostic criteria for SS include the Copenhagen criteria, the European classification criteria, and the International Collaborative Clinical Alliances Cohort (SICCA) criteria. The European classification criteria, which were revised by the American-European Consensus Group (AECG), are currently the most widely used diagnostic criteria. Even though no cure currently exists for SS, treatments are used to manage the symptoms and prevent further complications. These might include the use of salivary substitutes and artificial tears, or in the case of secondary SS, treatment of the underlying disease.
GlobalData epidemiologists estimate that within the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, Japan), as shown in Figure 1, the diagnosed prevalent cases of SS will increase from 3,210,390 cases in 2014 to 3,533,298 cases in 2024, at an Annual Growth Rate (AGR) of 1.01% over the forecast period. Throughout the forecast period, the US will have the highest number of diagnosed prevalent cases of SS in the 7MM. Similarly, the diagnosed prevalent cases of primary Sjogren's syndrome (pSS) will increase from 2,161,973 cases in 2014 to 2,384,551 cases in 2024, while the diagnosed prevalent cases of secondary Sjogren's syndrome (sSS) will increase from 1,048,417 cases in 2014 to 1,148,874 cases in 2024. During the forecast period, the proportion of ocular manifestations in the diagnosed prevalent cases of SS will range from a low of 87.00% in the UK and the US to a high of 98.00% in Italy. Similarly, approximately, 93.00-96.00% of prevalent SS cases will experience oral symptoms during the forecast period.
- The Sjogren's Syndrome (SS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for SS, which includes both primary Sjogren's syndrome (pSS) and secondary Sjogren's syndrome (sSS), in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of pSS, segmented by sex and age (from 18-19 years, then in 10-year age groups), diagnosed prevalent cases of sSS as well as SS and cases of ocular and oral manifestations in SS, in these markets.
- The SS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The SS EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global SS market.
- Quantify patient populations in the global SS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SS therapeutics in each of the markets covered.
Table of Contents
1. Table of Contents
- 1.1. List of Tables
- 1.2. List of Figures
- 2.1. Catalyst
- 2.2. Related Reports
- 2.3. Upcoming Reports
- 3.1. Disease Background
- 3.2. Risk Factors and Comorbidities
- 3.3. Global Trends
- 3.3.1. 7MM Diagnosed Prevalent Cases
- 3.3.2. 5EU Diagnosed Prevalent Cases
- 3.3.3. Japan Diagnosed Prevalent Cases
- 3.4. Forecast Methodology
- 3.4.1. Sources Used
- 3.4.2. Sources Not Used
- 3.4.3. Forecast Assumptions and Methods
- 3.5. Epidemiological Forecast for SS (2014-2024)
- 3.5.1. Diagnosed Prevalent Cases of SS
- 3.5.2. Age-Specific Diagnosed Prevalent Cases of pSS
- 3.5.3. Sex-Specific Diagnosed Prevalent Cases of pSS
- 3.5.4. Age-Standardized Diagnosed Prevalence of pSS
- 3.5.5. Ocular and Oral Manifestations
- 3.6. Discussion
- 3.6.1. Epidemiological Forecast Insight
- 3.6.2. Limitations of the Analysis
- 3.6.3. Strengths of the Analysis
- 4.1. Bibliography
- 4.2. About the Authors
- 4.2.1. Epidemiologists
- 4.2.2. Reviewers
- 4.2.3. Global Director of Therapy Analysis and Epidemiology
- 4.2.4. Global Head of Healthcare
- 4.3. About GlobalData
- 4.4. About EpiCast
- 4.5. Disclaimer
List of Tables
- Table 1: Risk Factors and Comorbidities for SS
- Table 2: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of pSS
- Table 3: 7MM, Sources Used to Forecast the Oral and Ocular Manifestations of SS
- Table 4: 7MM, Sources Not Used in the Epidemiological Analysis of SS
- Table 5: Diagnosed Prevalent Cases of SS, Age ≥18 Years, Both Sexes, N, 2014-2024
- Table 6: 7MM, Age-Specific Diagnosed Prevalent Cases of pSS, Age ≥18 Years, Both Sexes, N, 2014
- Table 7: 7MM, Sex-Specific Diagnosed prevalent Cases of pSS, Age ≥18 Years, N, 2014
List of Figures
- Figure 1: Diagnosed Prevalence Rate of SS in the 7MM, 2014
- Figure 2: Case Flow Map for pSS: US, Germany, Italy, UK, and Japan
- Figure 3: Case Flow Map for pSS: France and Spain
- Figure 4: 7MM, Diagnosed Prevalent Cases of pSS, Age ≥18 Years, Both Sexes, N, Selected Years, 2014-2024
- Figure 5: 7MM, Diagnosed Prevalent Cases of sSS, Age ≥18 Years, Both Sexes, N, Selected Years, 2014-2024
- Figure 6: 7MM Diagnosed Prevalent Cases of SS, Age ≥18 Years, Both Sexes, N, Selected Years, 2014-2024
- Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of pSS, Age ≥18 Years, Both Sexes, N, 2014
- Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of pSS, Age ≥18 Years, N, 2014
- Figure 9: 7MM, Age-Standardized Diagnosed Prevalence of pSS, Age ≥18 Years , 2014
- Figure 10: 7MM, Ocular and Oral Manifestations of SS in the Diagnosed Prevalent Cases of SS, Age ≥18 Years , 2014